CRBP Stock Price, Corbus Pharmaceuticals Holdings Quote, Chart

Market Summary

USD33.47-2.07

Market Closed

-5.82%

CRBP Stock Price

View Fullscreen

CRBP RSI Chart

CRBP Valuation

Market Cap

351.2M

Price/Earnings (Trailing)

-7.87

Price/Sales (Trailing)

466.16

Price/Free Cashflow

-9.73

CRBP Price/Sales (Trailing)

CRBP Profitability

Return on Equity

645.98%

Return on Assets

-157.76%

Free Cashflow Yield

-10.28%

CRBP Fundamentals

CRBP Revenue

Revenue (TTM)

881.7K

CRBP Earnings

Earnings (TTM)

-44.6M

Earnings Growth (Yr)

26.27%

Earnings Growth (Qtr)

20.21%

Breaking Down CRBP Revenue

Last 7 days

-8.4%

Last 30 days

-7.4%

Last 90 days

13.5%

Trailing 12 Months

335.2%

How does CRBP drawdown profile look like?

CRBP Financial Health

Current Ratio

0.74

CRBP Investor Care

Shares Dilution (1Y)

151.56%

Diluted EPS (TTM)

-8.28

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2021	2.8M	2.7M	1.5M	1.2M
2020	36.0M	7.2M	5.9M	3.9M
2019	5.8M	34.0M	35.5M	36.1M
2018	2.1M	2.6M	2.9M	4.8M
2017	2.8M	2.8M	2.8M	2.4M
2016	964.1K	1.3M	1.6M	1.9M
2015	0	0	0	648.4K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Corbus Pharmaceuticals Holdings Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 10, 2024	moran sean f.	acquired	53,610	30.00	1,787	chief financial officer
Mar 08, 2024	cormorant asset management, lp	bought	13,314,200	44.3806	300,000	-
Mar 07, 2024	cormorant asset management, lp	bought	10,013,400	40.0535	250,000	-
Feb 27, 2024	smethurst dominic	acquired	-	-	50,000	chief medical officer
Feb 12, 2024	cohen yuval	acquired	-	-	73,947	chief executive officer
Feb 12, 2024	moran sean f.	acquired	-	-	40,176	chief financial officer
Feb 02, 2024	cormorant asset management, lp	bought	14,250,000	19.00	750,000	-
Jan 26, 2024	cohen yuval	acquired	35,679	4.97	7,179	chief executive officer
Jan 26, 2024	cormorant asset management, lp	bought	9,111,940	32.2396	282,632	-
Jan 26, 2024	holmer alan f	acquired	3,126	4.97	629	-

Which funds bought or sold CRBP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	Cambridge Investment Research Advisors, Inc.	new	-	360,000	360,000	-%
Apr 24, 2024	Assenagon Asset Management S.A.	new	-	10,181,100	10,181,100	0.02%
Apr 24, 2024	Carmichael Hill & Associates, Inc.	unchanged	-	3,320	3,924	-%
Apr 23, 2024	BFSG, LLC	reduced	-98.36	-329	40.00	-%
Apr 19, 2024	JTC Employer Solutions Trustee Ltd	unchanged	-	32,000	39,000	-%
Apr 19, 2024	Cutler Group LLC / CA	new	-	31,000	31,000	0.01%
Apr 17, 2024	Annapolis Financial Services, LLC	sold off	-100	-139	-	-%
Apr 05, 2024	CWM, LLC	added	666	1,000	1,000	-%
Apr 05, 2024	NBC SECURITIES, INC.	new	-	1,000	1,000	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	-125,620	1,083,910	-%

Are Funds Buying or Selling CRBP?

Are funds buying CRBP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CRBP

No. of Funds

Unveiling Corbus Pharmaceuticals Holdings Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 18, 2024	cormorant asset management, lp	19.30%	2,025,000	SC 13G/A
Feb 28, 2024	millennium management llc	5.3%	544,276	SC 13G
Feb 14, 2024	k2 healthventures equity trust llc	7.8%	10,524,401	SC 13G
Feb 14, 2024	paradigm biocapital advisors lp	0.0%	0	SC 13G
Feb 14, 2024	k2 healthventures equity trust llc	7.5%	342,113	SC 13G/A
Feb 12, 2024	ra capital management, l.p.	4.1%	430,182	SC 13G
Feb 12, 2024	adage capital partners gp, l.l.c.	7.70%	796,392	SC 13G
Feb 09, 2024	integrated core strategies (us) llc	4.0%	412,321	SC 13G
Feb 05, 2024	paradigm biocapital advisors lp	9.0%	399,658	SC 13G
Feb 05, 2024	cormorant global healthcare master fund, lp	14.27%	1,475,000	SC 13G

Recent SEC filings of Corbus Pharmaceuticals Holdings Inc

View All Filings

Date Filed	Form Type	Document
Apr 11, 2024	4	Insider Trading
Apr 10, 2024	8-K	Current Report
Apr 10, 2024	DEFA14A	DEFA14A
Apr 02, 2024	ARS	ARS
Apr 02, 2024	DEF 14A	DEF 14A
Apr 02, 2024	DEFA14A	DEFA14A
Mar 22, 2024	PRE 14A	PRE 14A
Mar 20, 2024	EFFECT	EFFECT
Mar 20, 2024	10-K/A	Annual Report
Mar 20, 2024	424B3	Prospectus Filed

Peers (Alternatives to Corbus Pharmaceuticals Holdings Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.6B	6.8B	-1.15%	-18.78%	-8.61	5.92	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.46%	-27.26%	-41.1	9.9	76.23%	61.08%
BMRN	15.5B	2.4B	-6.36%	-11.66%	92.47	6.41	15.42%	18.43%
INCY	11.5B	3.7B	-9.50%	-30.40%	19.23	3.11	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.85%	-43.46%	-10.92	14.56	425.83%	18.94%
BBIO	4.3B	-	-18.25%	70.26%	-6.55	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-6.76%	2.03%	-14.16	12.52	440.80%	-27.84%
ARWR	2.7B	240.7M	-21.52%	-38.49%	-9.12	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-8.32%	-19.69%	-43.85	3.7	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.79%	-8.36%	24.23	4.35	85.90%	-14.05%
NVAX	552.8M	983.7M	-16.14%	-47.54%	-1.01	0.56	-50.36%	17.16%
CRBP	351.2M	881.7K	-7.41%	335.24%	-7.87	466.16	-77.61%	-5.33%
INO	236.5M	4.9M	-18.26%	4.12%	-1.75	48.6	-54.97%	51.71%
IBIO	5.9M	2.1M	47.83%	55.96%	-0.22	2.14	-13.45%	66.37%

Corbus Pharmaceuticals Holdings Inc News

Latest updates

Corbus Pharmaceuticals Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2021Q4	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1
Revenue	-	-	-	97.00	137	648	658	1,231	286	1,762	2,574	2,590	29,095	1,886	1,927	1,091	854	950	-	796	350	1,294
Operating Expenses	-	9,998	-	13,973	16,838	16,062	21,471	35,205	38,425	31,647	29,764	27,686	27,389	28,408	19,518	15,989	13,247	12,815	-	-	-	-
S&GA Expenses	-	226	-	5,277	5,572	5,341	5,360	7,682	7,739	7,699	6,276	5,534	5,208	6,625	3,737	3,181	2,988	3,050	-	-	-	-
R&D Expenses	-	380	-	8,696	11,265	10,721	16,110	27,523	30,686	23,948	23,488	22,152	22,181	21,784	15,781	12,808	10,260	9,765	-	-	-	-
Interest Expenses	-Infinity%	-390	-	-391	-401	-646	-684	-454	13.00	102	151	293	4.00	2.00	2.00	5.00	937*	2.00	-	-	-	-
Net Income	-Infinity%	-10,260	-	-2,176	-17,138	-16,065	-8,611	-34,895	-38,105	-29,656	-26,580	-20,790	2,153	-26,234	-17,306	-14,601	-12,069	-11,695	-	-	-	-
Net Income Margin	-42.5%	-51.76*	-36.33*	-28.57*	-28.70*	-34.60*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-1173.3%	-9,756	909	909	-17,476	-21,757	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-22.1%	28.00	36.00	44.00	52.00	66.00	74.00	82.00	96.00	108	120	121	140	102	96.00	98.00	65.00	49.00	68.00	84.00	101	47.00
Current Assets	-24.5%	24.00	31.00	38.00	46.00	60.00	67.00	75.00	88.00	100	112	112	130	92.00	85.00	88.00	55.00	38.00	58.00	75.00	93.00	44.00
Cash Equivalents	22.0%	14.00	11.00	8.00	7.00	17.00	12.00	26.00	57.00	25.00	37.00	36.00	67.00	85.00	82.00	63.00	47.00	32.00	55.00	73.00	90.00	42.00
Net PPE	-13.2%	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	3.00	4.00	4.00	4.00	4.00	5.00	5.00	5.00	5.00	3.00	3.00	3.00
Liabilities	-2.2%	35.00	36.00	34.00	35.00	33.00	32.00	33.00	35.00	39.00	42.00	44.00	49.00	57.00	67.00	50.00	43.00	43.00	38.00	37.00	59.00	19.00
Current Liabilities	1.1%	32.00	32.00	16.00	14.00	13.00	17.00	16.00	15.00	17.00	17.00	19.00	24.00	32.00	41.00	42.00	35.00	35.00	31.00	29.00	52.00	18.00
Long Term Debt	-	-	-	11.00	14.00	16.00	9.00	12.00	14.00	16.00	19.00	18.00	18.00	18.00	18.00	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	11.00	14.00	16.00	9.00	12.00	14.00	16.00	19.00	18.00	18.00	18.00	18.00	-	-	-	-	-	-	-
Shareholder's Equity	-2320.1%	-6.90	0.00	10.00	16.00	33.00	42.00	49.00	61.00	69.00	78.00	77.00	92.00	45.00	29.00	48.00	23.00	6.00	30.00	47.00	42.00	28.00
Retained Earnings	-1.9%	-436	-428	-418	-409	-392	-381	-372	-359	-349	-339	-337	-320	-304	-295	-260	-222	-192	-166	-145	-147	-121
Additional Paid-In Capital	0.2%	430	429	428	426	425	423	422	420	419	417	414	412	349	325	309	245	199	196	193	190	149
Shares Outstanding	0%	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	35.00	-	-	-	31.00	-	202	-	-	-	-	-	665	-	-	-	390	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	16.3%	-6,008	-7,176	-7,800	-15,114	-7,454	-7,245	-12,229	-10,615	-9,702	857	-17,528	-21,809	-18,224	-27,253	-26,607	-27,601	-22,561	-17,086	-16,390	10,318	-14,064
Share Based Compensation	-2.7%	799	821	823	1,026	1,269	1,346	1,513	1,592	1,793	2,599	2,507	2,580	2,341	3,631	3,348	3,138	3,098	2,978	2,817	3,089	1,950
Cashflow From Investing	-4.7%	10,388	10,896	8,807	5,550	11,780	-5,971	-18,696	42,962	-3,177	284	-13,098	-57,424	52.00	-56.80	-16.17	-463	-1,291	-1,194	-183	-73.61	-249
Cashflow From Financing	-132.1%	-1,904	-820	18.00	-113	234	-110	-330	-327	768	-102	-255	60,414	21,735	46,732	43,474	42,934	753	-24.65	-191	37,927	403

CRBP Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 31,167,660	$ 16,136,826
General and administrative	13,909,641	18,698,619
Litigation settlement	0	5,000,000
Total operating expenses	45,077,301	39,835,445
Operating loss	(45,077,301)	(39,835,445)
Other income (expense), net:
Other income (expense), net	3,389,440	(48,773)
Interest income (expense), net	(2,923,974)	(2,132,091)
Change in fair value of derivative liability	(2,582)	96,842
Foreign currency transaction gain (loss), net	11,101	(427,436)
Other income (expense), net	473,985	(2,511,458)
Net loss	$ (44,603,316)	$ (42,346,903)
Net loss per share, basic	$ (10.31)	$ (10.15)
Net loss per share, diluted	$ (10.31)	$ (10.15)
Weighted average number of common shares outstanding, basic	4,327,568	4,170,675
Weighted average number of common shares outstanding, diluted	4,327,568	4,170,675
Comprehensive loss:
Net Income (Loss)	$ (44,603,316)	$ (42,346,903)
Other comprehensive income (loss):
Change in unrealized gain (loss) on marketable debt securities	124,536	(63,647)
Total other comprehensive income (loss)	124,536	(63,647)
Total comprehensive loss	$ (44,478,780)	$ (42,410,550)

CRBP Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 13,723,681	$ 17,002,715
Investments	7,182,325	42,194,296
Restricted cash	192,475	192,475
Prepaid expenses and other current assets	2,447,549	791,616
Total current assets	23,546,030	60,181,102
Restricted cash	477,425	477,425
Property and equipment, net	973,214	1,613,815
Operating lease right-of-use assets	3,062,920	3,884,252
Other assets	212,804	155,346
Total assets	28,272,393	66,311,940
Current liabilities:
Notes payable	300,664	353,323
Accounts payable	3,178,516	2,173,963
Accrued expenses	11,030,506	5,999,252
Derivative liability	39,450	36,868
Operating lease liabilities, current	1,436,723	1,280,863
Current portion of long-term debt	15,908,214	2,795,669
Total current liabilities	31,894,073	12,639,938
Long-term debt, net of debt discount	0	15,984,426
Other long-term liabilities	44,411	22,205
Operating lease liabilities, noncurrent	3,238,631	4,675,354
Total liabilities	35,177,115	33,321,923
Stockholders' equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and December 31, 2022. See Note 12	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized, 4,423,683 and 4,171,297 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	442	417
Additional paid-in capital	429,780,375	425,196,359
Accumulated deficit	(436,683,983)	(392,080,667)
Accumulated other comprehensive loss	(1,556)	(126,092)
Total stockholders’ equity	(6,904,722)	32,990,017
Total liabilities and stockholders’ equity	$ 28,272,393	$ 66,311,940

About Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFÃƒÅ¸ expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

CEO	Dr. Yuval Cohen Ph.D.
WEBSITE	corbuspharma.com
INDUSTRY	Biotechnology
EMPLOYEES	33

Corbus Pharmaceuticals Holdings Inc Frequently Asked Questions

What is the ticker symbol for Corbus Pharmaceuticals Holdings Inc? What does CRBP stand for in stocks?

CRBP is the stock ticker symbol of Corbus Pharmaceuticals Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Corbus Pharmaceuticals Holdings Inc (CRBP)?

As of Thu Apr 25 2024, market cap of Corbus Pharmaceuticals Holdings Inc is 351.2 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRBP stock?

You can check CRBP's fair value in chart for subscribers.

What is the fair value of CRBP stock?

You can check CRBP's fair value in chart for subscribers. The fair value of Corbus Pharmaceuticals Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Corbus Pharmaceuticals Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CRBP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Corbus Pharmaceuticals Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether CRBP is over valued or under valued. Whether Corbus Pharmaceuticals Holdings Inc is cheap or expensive depends on the assumptions which impact Corbus Pharmaceuticals Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRBP.

What is Corbus Pharmaceuticals Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, CRBP's PE ratio (Price to Earnings) is -7.87 and Price to Sales (PS) ratio is 466.16. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRBP PE ratio will change depending on the future growth rate expectations of investors.